Lifespan extension therapy: Ciglitazone, an anti-diabetic medication,  may increase life span via up-regulation of its target gene BubR1, 25/October/2017, 11.20 pm

Natural product therapy for Diabetic nephropathy (DN):  Yangonin, isolated from Kava Kava, among others, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 25/October/2017, 1.04 am
October 24, 2017
Natural product-derived antiviral therapy against Neuroinvasive West Nile virus:  Andrographolide, one of the main components of Andrographis paniculata, increases the expression of RIPK3, promotes chemokines production, inhibits neuroinflammation, and restricts neuroinvasive West Nile virus production and pathogenesis in neurons via up regulation of its target gene, 25/October/2017, 11.27 pm
October 25, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Lifespan extension therapy: Ciglitazone, an anti-diabetic medication,  may increase life span via up-regulation of its target gene BubR1


What is known? 

Ciglitazone has been shown to possess neuroprotective activity. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Ciglitazoneby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing  Ciglitazone may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

 

Thereby, it may: (1) increase insulin sensitivity; (2) increase thermogenesis, lipolysis and oxidative metabolism; (3) inhibit obesity; (4) attenuate cognitive impairment; (5) delay diseases of aging; (6) slow down cardiac aging; (7) promote resistance to bone, immune and motor dysfunction; (8) promote tissue rejuvenation; and (9) prolong median life span. Thus, pharmacological formulations encompassing “Ciglitazone  or its analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Ciglitazone increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: Ciglitazone, an anti-diabetic medication,  may increase life span via up-regulation of its target gene BubR1, 25/October/2017, 11.20 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.